SARS-CoV2 antibody tests: not suited for individual diagnosis?
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
French Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Belgian Bone Therapeutics SA has secured 11m to foster development of its late stage pipeline candidates.
Cevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
German vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.